Cyclin C Variants and Diagnostic and Therapeutic Uses Thereof (SJ-99-0011)



Technology Name
(St. Jude Reference #)
Cyclin C variants and diagnostic and therapeutic uses thereof (SJ-99-0011)
Description This invention describes a truncated cyclin C protein that acts as an endogenous cyclin C inhibitor which can be used to develop diagnostic and therapeutic treatments for a number of different cancers. The level of truncated cyclin C expression in tumors can be modulated by either increasing (through the use of gene therapy vectors) or decreasing (using anti-sense RNA technology) the amount of truncated cyclin C protein within the cancerous cells.  In addition, this invention could also be developed into a preventive treatment in precancerous lesions that are known to progress into cancer, such as dysplasias of the cervix, esophagus and lung, by manipulating the level of truncated cyclin C expression.
Keywords Cyclin C, cancer therapeutic and diagnostic, cell cycle regulation
Granted Patents or Published Applications U.S. Patent Nos. 6,075,123; 6,306,648
Related Scientific References

Kidd, et al., “Regulated expression of a cell division control-related protein kinase during Development”, Cell Growth & Differ. 2:85-93  (1991); Lahti, et al.,

“Alterations in the PITSLRE protein kinase gene complex on chromosome1p36 in childhood neuroblastoma”,  Nature Genetics 7:370-375 (1994);

Lahti, et al., “PITSLRE protein kinase activity is associated with apoptosis”, Mol. Cell. Biol. 15:1-11 (1995).

Licensing Opportunities We are currently seeking licensing opportunities in all fields for the development of this technology.

 

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.

 

Last update: June 2006